Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics.
Despite multiple clinical trials utilizing a spectrum of therapeutic modalities, melanoma remains a disease with dismal outcomes in patients with advanced disease. However, it is now clear that melanoma is not a single entity, but can be molecularly divided into subtypes that generally correspond to the anatomical location of the primary melanoma. Melanomas from acral lentiginous, mucosal, and chronic sun-damaged sites frequently harbor activating mutations and/or increased copy number in the KIT tyrosine kinase receptor gene, which are very rare in the more common cutaneous tumors. Multiple case reports and early observations from clinical trials suggest that targeting mutant KIT with tyrosine kinase inhibitors is efficacious in KIT mutant melanoma. This review recounts what is known about the role of KIT in melanocyte maturation, our current understanding of KIT genetic aberrations in melanoma, and how this knowledge is being translated into clinical oncology.
Woodman
Scott E
SE
Departments of Melanoma Medical Oncology and Systems Biology, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA. swoodman@mdanderson.org
Davies
Michael A
MA
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008545:Melanoma / Q000188:drug therapy*; D009154:Mutation; D019009:Proto-Oncogene Proteins c-kit / Q000187:drug effects* / Q000235:genetics; D012878:Skin Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D019009:Proto-Oncogene Proteins c-kit
EMBO J. 1987 Nov;6(11):3341-51
2448137
Br J Haematol. 2007 Jul;138(1):12-30
17555444
Br J Cancer. 2008 Dec 16;99(12):2065-9
19018266
J Invest Dermatol. 2006 May;126(5):1102-10
16410786
Hum Pathol. 2005 May;36(5):486-93
15948115
Hum Pathol. 2006 May;37(5):520-7
16647948
J Physiol. 2007 Jan 1;578(Pt 1):33-42
17095561
J Clin Oncol. 2004 Nov 15;22(22):4514-22
15542802
Mol Cancer Ther. 2009 Aug;8(8):2079-85
19671763
Cell. 1988 Oct 7;55(1):185-92
2458842
Pigment Cell Melanoma Res. 2008 Aug;21(4):492-3
18510589
Clin Cancer Res. 2008 Nov 1;14(21):6821-8
18980976
N Engl J Med. 2004 Sep 2;351(10):998-1012
15342808
Nature. 1986 Apr 3-9;320(6061):415-21
3007997
Blood. 1995 Feb 1;85(3):641-9
7530502
Clin Cancer Res. 2008 Dec 1;14(23):7726-32
19047099
Stem Cells. 2005;23(1):16-43
15625120
Nature. 1988 Sep 1;335(6185):88-9
2457811
Mol Biol Cell. 1992 Mar;3(3):349-62
1378327
Virchows Arch. 2008 Jan;452(1):27-32
18066592
Oncogene. 1992 Jan;7(1):51-6
1371338
Nat Clin Pract Oncol. 2008 Dec;5(12):737-40
18936790
Cell Mol Life Sci. 2004 Oct;61(19-20):2535-48
15526160
J Clin Oncol. 2006 Sep 10;24(26):4340-6
16908931
Trends Genet. 1993 Aug;9(8):285-90
7691001
EMBO J. 1991 Sep;10(9):2451-9
1714377
Am J Hum Genet. 1992 Feb;50(2):261-9
1370874
Cancer. 2006 May 1;106(9):2005-11
16565971
Mod Pathol. 2009 Nov;22(11):1446-56
19718013
Int J Cancer. 2007 Jul 15;121(2):257-64
17372901
Br J Cancer. 2008 Sep 2;99(5):734-40
18728664
Int J Cancer. 2009 Feb 15;124(4):862-8
19035443
N Engl J Med. 2005 Nov 17;353(20):2135-47
16291983
Br J Cancer. 2005 Apr 25;92(8):1398-405
15846297
J Endocrinol Invest. 2000 Oct;23(9):609-15
11079457
J Clin Oncol. 2008 Apr 20;26(12):2046-51
18421059
Blood. 1993 Aug 15;82(4):1151-8
7688988
Oncogene. 1996 Dec 5;13(11):2339-47
8957075
Oncogene. 2010 Jan 14;29(2):227-36
19802003
Annu Rev Pathol. 2008;3:557-86
18039140
Pigment Cell Melanoma Res. 2010 Feb;23(1):14-26
20025711
Mol Cancer Res. 2009 Sep;7(9):1525-33
19737976